FIELD: biotechnology.
SUBSTANCE: present invention refers to immunogenic peptides containing a T-cell epitope, and can be used in medicine for treating, suppressing or preventing such diseases, as infectious or allergic diseases and autoimmune diseases for prevention or suppression of transplant rejection, or for destruction of tumor cells.
EFFECT: disclosed modified antigenic peptides are capable of inducing stronger responses of CD4+ T-cells compared to unmodified antigenic peptides; modification is an addition of cysteine, a cysteine insert or a mutation to a residue cysteine in a position adjacent to the MHC peptide binding site but outside it.
21 cl, 3 dwg, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOGENIC PEPTIDES FOR APPLICATION FOR PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES, THE IMMUNE RESPONSES TO ALLOGENEIC FACTORS, ALLERGIC DISEASES, TUMOUR, TRANSPLANT REJECTION AND IMMUNE RESPONSES AGAINST VIRAL VECTORS USED FOR GENETIC THERAPY OR GENETIC VACCINATION | 2011 |
|
RU2615460C2 |
| NEW IMMUNOGENIC PEPTIDES | 2015 |
|
RU2709711C2 |
| IMMUNOSTIMULATING COMPOSITIONS | 2016 |
|
RU2732118C2 |
| POLYEPITOPE ANTI-TUMOUR VACCINE STRUCTURE CONTAINING EPITOPES OF TUMOR-ASSOCIATED ANTIGENS, PHARMACEUTICAL COMPOSITION AND ITS APPLICATION FOR STIMULATING SPECIFIC ANTI-TUMOR IMMUNE RESPONSE | 2016 |
|
RU2684235C2 |
| MODULATION OF ANTIGEN IMMUNOGENICITY BY ADDITION OF EPITOPES RECOGNIZED BY NKT CELLS | 2011 |
|
RU2603075C2 |
| PEPTIDES AND DIABETES TREATMENT METHODS | 2018 |
|
RU2761653C2 |
| NOVEL CELL-PENETRATING PEPTIDES | 2013 |
|
RU2670488C2 |
| PREVENTIVE OR THERAPEUTIC POLYEPITOPIC ANTI-TUBERCULOSIS VACCINE CONSTRUCTION PROVIDING INDUCTION OF CELLULAR IMMUNE RESPONSE OF CD4+ OR CD8+ T-LYMPHOCYTES | 2011 |
|
RU2539035C2 |
| POLYPEPTIDES | 2011 |
|
RU2581800C2 |
| INTRACELLULAR DELIVERY OF BIOMOLECULES FOR IMMUNE RESPONSE MODULATION | 2019 |
|
RU2819143C2 |
